Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 11, 2023 17:16 ET | Source: Sagaliam Acquisition Corp

SAGALIAM ACQUISITION CORP. ANNOUNCES RECEIPT OF NASDAQ DELISTING LETTER

New York, NY, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Sagaliam Acquisition Corp. (NASDAQ: “SAGAU”, “SAGA”, SAGAR”) (the “Company”) received a delisting notification letter (“Notice”) from the Listing...
June 26, 2023 17:00 ET | Source: Imunon, Inc.

Imunon Reports Inducement Grants under NASDQ Listing Rule 5646(c)(4)

LAWRENCEVILLE, N.J., June 26, 2023 (GLOBE NEWSWIRE) -- Imunon, Inc. (NASDAQ: IMNN), a clinical-stage drug development company focused on DNA-based immunotherapy and next-generation vaccines, today...
March 21, 2023 16:30 ET | Source: Imunon, Inc.

Imunon Reports Inducement Grants under NASDQ Listing Rule 5646(c)(4)

LAWRENCEVILLE, N.J., March 21, 2023 (GLOBE NEWSWIRE) -- Imunon, Inc. (NASDAQ: IMNN), a clinical-stage drug development company focused on DNA-based immunotherapy and next-generation vaccines, today...
March 15, 2023 14:00 ET | Source: Imunon, Inc.

IMUNON Announces Abstract Accepted for Presentation at the American Association for Cancer Research Annual Meeting

LAWRENCEVILLE, N.J., March 15, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug development company, today announced that an abstract related to the Company’s DNA-based...
January 12, 2023 08:30 ET | Source: Imunon, Inc.

IMUNON Receives $1.6 Million from Sale of its New Jersey Net Operating Losses

Non-dilutive funding strengthens balance sheet and extends current operating runway into 2025The sale of an additional $1.8 million of unused New Jersey NOLs expected in 2023 LAWRENCEVILLE, NJ,...
December 14, 2022 08:30 ET | Source: Imunon, Inc.

IMUNON Reports Inducement Grants under NASDQ Listing Rule 5646(c)(4)

LAWRENCEVILLE, N.J., Dec. 14, 2022 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug development company focused on DNA-based immunotherapy and next-generation vaccines, today...
October 03, 2022 17:00 ET | Source: Imunon, Inc.

Imunon Appoints James E. Dentzer to its Board of Directors

CEO of Curis brings extensive biopharmaceutical financial experience to the Board LAWRENCEVILLE, N.J., Oct. 03, 2022 (GLOBE NEWSWIRE) -- Imunon, Inc. (Nasdaq: IMNN), a clinical-stage drug...
October 03, 2022 08:00 ET | Source: Imunon, Inc.

Imunon Reports Partial Results from Ongoing Non-human Primate Study

Supports PLACCINE Platform as a Viable Alternative to mRNA Vaccines LAWRENCEVILLE, N.J., Oct. 03, 2022 (GLOBE NEWSWIRE) -- Imunon, Inc. (NASDAQ: IMNN), a clinical-stage drug development company,...
September 29, 2022 17:00 ET | Source: Imunon, Inc.

Imunon Reports Inducement Grants under NASDQ Listing Rule 5646(c)(4)

LAWRENCEVILLE, N.J., Sept. 29, 2022 (GLOBE NEWSWIRE) -- Imunon, Inc. (NASDAQ: IMNN), a clinical-stage drug development company focused on DNA-based immunotherapy and next-generation vaccines, today...
September 12, 2022 18:30 ET | Source: Celsion Corporation

Celsion Corporation Presentation Time at the H.C. Wainwright 24th Annual Global Investment Conference Changed to 4:30 p.m. ET on September 13

LAWRENCEVILLE, N.J., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage drug development company, announces that Dr. Corinne Le Goff, President and Chief...

Next Page keyboard_arrow_right